Cefcanel
Cefcanel is an orally active cephalosporin and antibacterial agent. Cefcanel inhibits growth of methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, Haemophilus influenzae, Moraxella catarrhalis. Cefcanel acts as a substrate hydrolyzed by TEM-1, TEM-3, and Moraxella Bro-1 beta-lactamases.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 41952-52-7
- 화학식: C19H18N4O5S3
- 분자량:478.57
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
All Beta-lactamase Isoforms
More
Biological Activity
제품 설명
In Vitro
Cefcanel (18-20 h) exhibits potent in vitro activity against a variety of aerobic Gram-positive bacteria, including methicillin-sensitive *Staphylococcus aureus* (MIC90 1 μg/mL) and methicillin-sensitive *Staphylococcus epidermidis* (MIC90 1 μg/mL)[1].
Cefcanel (18-20 h) exhibits variable in vitro activity against aerobic Gram-negative bacteria. It shows potent activity against *Klebsiella pneumoniae* (MIC90 2 μg/mL), *Citrobacter diversus* (MIC90 2 μg/mL), *Aeromonas hydrophila* (MIC90 1 μg/mL), *Haemophilus influenzae* (MIC90 1 μg/mL) and *Moraxella catarrhalis* (MIC90 1 μg/mL), but is inactive against *Serratia marcescens*, *Pseudomonas aeruginosa* and *Acinetobacter calcoaceticus*[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 41952-52-7
-
분자량 478.57
-
화학식 C19H18N4O5S3
-
SMILES
OC(C1=C(CSC2=NN=C(C)S2)CS[C@@]([C@@H]3NC([C@@H](C4=CC=CC=C4)O)=O)([H])N1C3=O)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cefcanel Related Classifications
HY-105560 Related Classifications
Powered by Bioz
Keywords
- Cefcanel
- 41952-52-7
- Bacterial
- Beta-lactamase
- Escherichia coli
- methicillin-susceptible Staphylococcus aureus
- Haemophilus influenzae
- Clostridium perfringens
- Streptococcus pyogenes
- Moraxella catarrhalis
- Streptococcus pneumoniae
- beta-lactamases
- methicillin-susceptible Staphylococcus epidermidis
- Klebsiella pneumoniae
- Inhibitor
- inhibitor
- inhibit